8 not yet recruiting, 3 recruiting, 1 active not recruiting. 7 Phase 3, 3 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Not yet recruiting 6, Recruiting 1 |
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow SYS6010: new trials by email Literature Review of SYS6010 trials Research Report on SYS6010
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC SYS6010, Investigator's Choice of monotherapy - Head and Neck Squamous Cell Carcinoma | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 340 | 2026-08-15 | 2026-08-11 |
| A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC SYS6010 - NSCLC | Phase 1 | Not yet recruiting | Sichuan University | 21 | 2026-06-30 | 2026-07-09 |
| A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) SYS6010, Enlonstobart, Tislelizumab - Non-small Cell Lung Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 570 | 2026-06-25 | 2026-06-26 |
| A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC SYS6010, Osimertinib, platinum-pemetrexed - NSCLC | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 680 | 2026-06-01 | 2026-05-13 |
| A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer SYS6010, Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine) - Recurrent or Metastatic Breast Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 400 | 2026-04-01 | 2026-02-12 |
| SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma SYS6010, Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel) - Locally Advanced/Metastatic/Recurrent ESCC | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 436 | 2026-03-18 | 2026-02-18 |
| SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ SYS6010, Docetaxel - Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 506 | 2026-03-10 | 2026-03-04 |
| A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer SYS6010, Osimertinib, Pemetrexed - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 120 | 2025-11-30 | 2025-12-05 |
| A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors sirolimus (albumin-bound), DP303c, SYS6043 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 444 | 2025-11-13 | 2025-11-28 |
| Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） SYS6010, Pemetrexed, Cisplatin - EGFR-mutated Locally Advanced or Metastatic NSCLC | Phase 3 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 380 | 2025-03-30 | 2026-07-01 |
| A Study of SYS6010 in Combination With SYH2051 in Patients With Advanced Colorectal Cancer and Other Gastrointestinal Tumors SYS6010, SYH2051 - Colorectal Cancer, Gastric Cancer (GC) | Not applicable | Active not recruiting | Fujian Cancer Hospital | 25 | 2024-04-18 | 2025-08-05 |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors CPO301 - Cancer, Cancer, Lung | Phase 1 | Recruiting | Conjupro Biotherapeutics, Inc. | 132 | 2023-06-06 | 2026-03-20 |
Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Digestive System Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
CSPC Megalith Biopharmaceutical Co.,Ltd. (8) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Conjupro Biotherapeutics, Inc. (1) · Fujian Cancer Hospital (1) · Sichuan University (1)
China (4) · Canada (1) · United States (1)
Shun Lu, Doctor (1)